Additionally, contrary to PrPC, no reduction in Sho was observed in transgenic models of other neurodegenerative diseases as of Alzheimer’s and Parkinson’s diseases or frontal dementia, expressing the disease-related mutant β-amyloid precursor protein, α-synuclein or tau [47,65]. The gene discussed is MAPT; the disease is neurodegenerative disease.